Our corporate governance architecture
Our corporate governance architecture is designed to enhance the effectiveness of our Board and support their oversight of the GSK Leadership Team (GLT) in delivering our Ahead Together strategy. This framework supports a clear division of responsibilities, appropriate distribution of workload to focused Board committees, and highly committed Directors who are motivated to drive the success of the company.
Our evolving governance framework equips us to navigate industry challenges, maintain our license to operate and drive sustainable growth as a pure biopharma business.
Ahead Together oversight
Our Board focuses on priorities agreed for the year to support delivery of GSK’s corporate strategy encapsulated in our Ahead Together ambitions. Our Board and management agendas are completely aligned with a clear focus on the three time periods that management communicate on – financial performance to 2026, pipeline progress and business development to support the growth ambitions to 2031 as well as the science and technologies that support the long-term growth of the business beyond 2031.
Prioritising engagement
We engage with stakeholders, to understand their expectations and our ever changing landscape. Through ongoing dialogue, we address emerging issues and make decisions to meet their needs. Our Board gathers stakeholder perspectives through multiple channels, including our committees, our leadership team, insights reports, investor discussions, and meetings such as the Annual Governance Meeting and AGM. Our CEO and CFO meet with investors, analysts, and journalists to present our half-year and full-year results. For dividend details, see our dividend calendar.
Responsible business oversight
Responsible business is embedded in our strategy for sustainable performance and long-term growth. We track progress in six priority areas to build trust: access, global health and health security, environment, inclusion, ethical standards, and product governance. Our Corporate Responsibility Committee oversees and monitors GLT’s progress against these six priority areas to build trust. This includes regularly reviewing our Responsible Business Performance Rating and the detailed Rating metrics. Progress against our priority areas are published annually in our Responsible Business Performance Report.
Downloads
- Annual Report 2024 (PDF - 8.9MB)
- Governance And Remuneration Report 2024 (PDF - 2.7MB)
- 2025 Remuneration Policy (PDF - 241.8KB)
- Non Executive Directors’ Fees (PDF - 97.4KB)
- Articles of Association (PDF - 432.7KB)
- GSK Group company names and addresses (PDF - 157.6KB)
- Corporate Governance and Section 172 statements for applicable UK subsidiaries (PDF - 108.2KB)
- Expectations of External Auditor (PDF - 129.2KB)
